Literature DB >> 15361556

2004 Dr. Gary J. Becker Young Investigator Award: Relative thermosensitivity of cytotoxic drugs used in transcatheter arterial chemoembolization.

Kamran Ahrar1, Robert A Newman, Jihai Pang, Mary K Vijjeswarapu, Michael J Wallace, Kenneth C Wright.   

Abstract

PURPOSE: Large hepatocellular carcinoma tumors are being treated increasingly with a combination of transcatheter arterial chemoembolization (TACE) and radiofrequency (RF) ablation. However, the high temperatures reached during RF ablation may reduce the cytotoxic effects of antineoplastic agents, but this has not been studied. Therefore, in the present study, the relative thermosensitivity of cytotoxic drugs commonly used in TACE was studied.
MATERIALS AND METHODS: The relative cytotoxic effects of cisplatin, doxorubicin HCl, and mitomycin on the growth of human colon HT29 and lung A549 adenocarcinoma cells before and after heating each drug in solution was determined from the standpoints of different durations of exposure (15, 30, 60, 90, and 120 minutes) at a fixed temperature (120 degrees C) and exposure to different temperatures (60 degrees C, 80 degrees C, 100 degrees C, and 120 degrees C) for a fixed period of time (2 hours). After 72 hours of exposure of the cells to each drug, relative cell growth inhibition was assessed by MTT assay, and 50% inhibitory concentration (IC(50)) values were calculated for each cytotoxic agent. Finally, the heat-dependent degradation of mitomycin and doxorubicin was analyzed with use of tandem electrospray mass spectrometry.
RESULTS: The relative cytotoxic activities (shown by cell growth inhibition and IC(50) values) of cisplatin, doxorubicin, and mitomycin heated to 120 degrees C for 2 hours decreased by factors of 1.35 (range, 1-1.75), 9.5 (range, 8.5-10.5), and 7.05 (range, 3.5-12), respectively. The cytotoxic activities of doxorubicin and mitomycin continued to decrease with incremental increases in temperature. Similarly, with incremental increases in the duration of exposure to heat, the cytotoxic activities of doxorubicin and mitomycin decreased. Mass spectrometric analysis of residual drug content showed that a 2-hour exposure to a temperature of 120 degrees C caused doxorubicin and mitomycin to degrade by 95% and 84%, respectively.
CONCLUSIONS: The cytotoxicity of cisplatin is not affected by heat. The cytotoxicities of doxorubicin and mitomycin are reduced by high temperature and duration of exposure to heat. Although degradation of cytotoxicity starts at 60 degrees C and after 30 minutes of exposure to heat, statistically significant changes are encountered at 100 degrees C and after 90 minutes of exposure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15361556     DOI: 10.1097/01.RVI.0000136829.36643.ED

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  12 in total

Review 1.  Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art.

Authors:  Roberto Iezzi; Maurizio Pompili; Alessandro Posa; Giuseppe Coppola; Antonio Gasbarrini; Lorenzo Bonomo
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

2.  Does doxorubicin survive thermal ablation? Results of an ex vivo bench top study.

Authors:  Joseph D Morrison; Collin K Schlager; Amanda E Lee; Richard B van Breemen; Ron C Gaba
Journal:  Diagn Interv Radiol       Date:  2018 Jan-Feb       Impact factor: 2.630

Review 3.  Synergy in cancer treatment between liposomal chemotherapeutics and thermal ablation.

Authors:  Muneeb Ahmed; Marwan Moussa; S Nahum Goldberg
Journal:  Chem Phys Lipids       Date:  2011-12-14       Impact factor: 3.329

4.  Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC).

Authors:  Andrea Veltri; Paolo Moretto; Andrea Doriguzzi; Eva Pagano; Giovanna Carrara; Giovanni Gandini
Journal:  Eur Radiol       Date:  2005-10-14       Impact factor: 5.315

Review 5.  Combining locoregional therapies in the treatment of hepatocellular carcinoma.

Authors:  Mikhail C S S Higgins; Michael C Soulen
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

6.  Single-step multimodal locoregional treatment for unresectable hepatocellular carcinoma: balloon-occluded percutaneous radiofrequency thermal ablation (BO-RFA) plus transcatheter arterial chemoembolization (TACE).

Authors:  R Iezzi; V Cesario; L Siciliani; M Campanale; A M De Gaetano; M Siciliano; S Agnes; F Giuliante; A Grieco; M Pompili; G L Rapaccini; A Gasbarrini; L Bonomo
Journal:  Radiol Med       Date:  2013-01-28       Impact factor: 3.469

7.  Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection.

Authors:  Jin Woong Kim; Sang Soo Shin; Jae Kyu Kim; Sung Kyu Choi; Suk Hee Heo; Hyo Soon Lim; Young Hoe Hur; Chol Kyoon Cho; Yong Yeon Jeong; Heoung Keun Kang
Journal:  Korean J Radiol       Date:  2013-07-17       Impact factor: 3.500

Review 8.  Local ablative treatments for hepatocellular carcinoma: An updated review.

Authors:  Antonio Facciorusso; Gaetano Serviddio; Nicola Muscatiello
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-11-06

9.  Tumor angiogenesis after heated lipiodol infusion via the hepatic artery in a rabbit model of VX2 liver cancer.

Authors:  Wei Cao; Xiang Xu; Juliang Zhang; Yunyou Duan
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

10.  A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats.

Authors:  F Aarts; T Hendriks; O C Boerman; M J Koppe; W J G Oyen; R P Bleichrodt
Journal:  Ann Surg Oncol       Date:  2007-07-25       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.